arrow
S

Saiama N. Waqar

Washington University School of Medicine
H指数:39
被引数:6,831

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating the safety and efficacy of chemotherapy in patients with relapsed small cell lung cancer combined with allopurinol and MycoPhenolate (CLAMP)

评估阿洛普利诺和霉酚酸联合化疗在复发小细胞肺癌患者中的安全性和有效性(CLAMP)

2026-05-010
PRE
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)

I期临床试验:评估ataxia telangiectasia和Rad3-related抑制剂berzosertib联合伊立替康治疗晚期实体瘤患者的疗效(ETCTN 9938)

Cancer
IF5.1
2025-10-290
PRE
Efficacy of neratinib-based therapy in ERBB2-mutant lung adenocarcinomas: findings from 2 international phase 2 studies

奈拉替尼为基础疗法在ERBB2突变型肺腺癌中的疗效:2项国际II期研究的结果

2025-10-010
PRE
Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer

分子肿瘤委员会:国际肺癌研究协会的共识声明

2025-07-070
PRE
The changing landscape of small cell lung cancer

小细胞肺癌的景观变化

CANCER
IF5.1
2024-03-127
PRE
First-in-class first-in-human phase 1 trial and translational study of the mono(ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 in patients with selected advanced solid tumors
2023-04-141
PRE
Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)
2023-04-040
PRE
Trends in Stage I Lung Cancer

I期肺癌的发展趋势

2023-03-0117
PRE
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma

抗表皮生长因子受体抗体药物偶联物serclutamab talirine的I期研究: 晚期胶质母细胞瘤的安全性,药代动力学和抗肿瘤活性

2022-12-217
OAAI
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
2022-09-12133
OAAI